P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Detalles Bibliográficos
Autores principales: Zheng, Xinhui, Cao, Yigeng, Jiang, Erlie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430681/
http://dx.doi.org/10.1097/01.HS9.0000972012.84926.12
_version_ 1785091024810409984
author Zheng, Xinhui
Cao, Yigeng
Jiang, Erlie
author_facet Zheng, Xinhui
Cao, Yigeng
Jiang, Erlie
author_sort Zheng, Xinhui
collection PubMed
description
format Online
Article
Text
id pubmed-10430681
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104306812023-08-17 P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Zheng, Xinhui Cao, Yigeng Jiang, Erlie Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430681/ http://dx.doi.org/10.1097/01.HS9.0000972012.84926.12 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Zheng, Xinhui
Cao, Yigeng
Jiang, Erlie
P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
title P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_full P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_fullStr P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_full_unstemmed P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_short P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
title_sort p1281: refractory patients with favorable/intermediate-risk aml benefit from azacytidine maintenance therapy after allogeneic hematopoietic stem cell transplantation
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430681/
http://dx.doi.org/10.1097/01.HS9.0000972012.84926.12
work_keys_str_mv AT zhengxinhui p1281refractorypatientswithfavorableintermediateriskamlbenefitfromazacytidinemaintenancetherapyafterallogeneichematopoieticstemcelltransplantation
AT caoyigeng p1281refractorypatientswithfavorableintermediateriskamlbenefitfromazacytidinemaintenancetherapyafterallogeneichematopoieticstemcelltransplantation
AT jiangerlie p1281refractorypatientswithfavorableintermediateriskamlbenefitfromazacytidinemaintenancetherapyafterallogeneichematopoieticstemcelltransplantation

Ejemplares similares